EMBER-4 Clinical Trial for Early Breast Cancer
The EMBER-4 clinical trial has been launched to evaluate the effectiveness of imlunestrant compared to standard hormone therapy for patients with early-stage breast cancer that is estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-).
This pioneering study aims to determine how well imlunestrant can help reduce the risk of cancer recurrence in participants who have already undergone 2 to 5 years of adjuvant endocrine therapy and are at a higher-than-average risk for their cancer returning.
Participants in the trial could be involved for up to 10 years, contributing valuable data to improve treatment outcomes.
Those eligible for the study will be randomly assigned to one of two treatment groups: the experimental arm receiving imlunestrant or the active comparator arm receiving the investigator’s choice of standard endocrine therapy.
To qualify, patients must be 18 years or older, have a history of receiving 2 to 5 years of adjuvant endocrine therapy for ER+, HER2- early breast cancer, and demonstrate an increased risk of recurrence.
This targeted approach aims to find more effective treatment strategies for a challenging patient population.
The EMBER-4 trial is being conducted at multiple esteemed hospitals across Ireland, including Beacon Hospital, Beaumont Hospital, Bon Secours Cork, Cork University Hospital, Sligo University Hospital, St James’s Hospital, St Vincent’s University Hospital, University Hospital Galway, and University Hospital Waterford.
If you are interested in participating in this groundbreaking study, the first step is to discuss it with your healthcare provider or the cancer trials research team at your hospital.
For more information, including contact details for cancer trials research units in Ireland, you can visit the relevant website.
Your participation in the EMBER-4 trial could not only provide you with access to innovative treatments but also contribute to the advancement of breast cancer care, potentially benefiting future patients facing similar challenges.
This trial marks an important step forward in the ongoing quest to improve outcomes for individuals diagnosed with early breast cancer.
For more posts like this, visit oncodaily.com
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023